Daohong Zhou

Daohong Zhou M.D.

Professor of Pharmacodynamics and Radiation Oncology, Henry E. Innes Professorship of Cancer Research, Associate Director for Translation and Drug Development

Department: Pharmacodynamics
Business Phone: (352) 294-8952
Business Email: zhoudaohong@cop.ufl.edu

About Daohong Zhou

Dr. Daohong Zhou is a Professor in the Department of Pharmacodynamics at the College of Pharmacy and a Professor in the Department of Radiation Oncology at the College of Medicine, University of Florida (UF) at Gainesville. He serves as the Associate Director for Translation and Drug Development and the Henry E. Innes Professorsip of Cancer Research at the UF Health Cancer Center. Dr. Zhou received his medical (1978-1983) and graduate (1983-1986) training from Yunyany Medical College of Tongji Medical University and Henan Medical University, respectively; and his postdoctoral training (1990-1992) at the Johns Hopkins University School of Medicine. Before he joined UF in 2018, he was a Professor of Pharmaceutical Sciences and the Deputy Director of the Division of Radiation Health at the College of Pharmacy and the Associate Director for Basic Research at the Winthrop P. Rockefeller Cancer Institute in the University of Arkansas for Medical Sciences (UAMS).

Dr. Daohong Zhou has published more than 100 peer reviewed scientific articles and book chapters. His research has been well supported by grants from various private and government funding agencies, including the National Cancer Institute (NCI) and National Institute of Allergy and Infectious Disease (NIAID). Dr. Daohong Zhou serves on several national and international peer review panels and as a reviewer for various scientific publications. He was a regular member of the Radiation Therapeutics and Biology Study Section at the National Institutes of Health (NIH) and a co-chair of the Panel Meeting for General Program of the Dept. of Health Sciences (Hematology) at the National Natural Science Foundation of China (NSFC). He is a Councilor of the Radiation Research Society (http://www.radres.org) and a co-founder of Unity Biotechnology (http://unitybiotechnology.com), a biotech that develops senolytic drugs for aging and age-related diseases.

Honors & Awards

Henry E. Innes Professorsip of Cancer Research
2018-Current · University of Florida
Established Investigator of Year Award
2016 · The Arkansas Biosciences Institute
Scholar
2010-2018 · Arkansas Research Alliance
The Winthrop Rockefeller Endowed Chair for Leukemia and Lymphoma Research
2010-2018 · University of Arkansas for Medical Sciences

Research Profile

Dr. Zhou’s research has been focused on investigation ofthe long-term effects of genotoxic stress/DNA damage induced by ionizing radiation (IR) and chemotherapy on hematopoietic stem cell (HSC) self-renewal and genomic stability; and the role of HSC injury in IR- and chemotherapy-induced long-term bone marrow suppression and leukemogenesis. His studies has led to a better understanding of the cellular and molecular mechanisms by which IR and chemotherapy cause normal tissue damage and the discovery of the first potent and broad-spectrum senolytic drug, ABT263-a specific Bcl-2/xl inhibitor, that can selectively kill senescent cells to rejuvenate both prematurely senescent tissue stem cells induced by IR and tissue stem cells in normally aged mice. This discovery may lead to new therapeutics for various age-related diseases and the side effects induced by chemotherapy and IR. More recently, he developed several proteolysis targeting chimeras (PROTACs) that can target Bcl-xl and other proteins of interest for degradation via the ubiquitination and proteasome system. He found that Bcl-xl PROTACs can selectively induce Bcl-xl degradation in senescent cells and various cancer cells but not in platelets, suggesting that Bcl-xl PROTACs have the potential to be developed as a better senolytic and anticancer agent than ABT263 by not causing thrombocytopenia. Using the PROTAC drug development platform, he is developing additional specific antitumor agents.

Grants

August 2019ACTIVE
Develop BCL-xL proteolysis targeting chimeras as safer and better senolytics
NATL INST OF HLTH NIA · Principal Investigator
September 2018ACTIVE
Cancer Therapy-induced Long-term Bone Marrow Injury
NATL INST OF HLTH NCI · Principal Investigator
September 2018ACTIVE
NCI Clinical and Translational Exploratory/ Developmental Studies
NATL INST OF HLTH NCI · Project Manager
August 2018 – August 2019
Discovery and Target Identification of Senolytic Agents
NATL INST OF HLTH NIA ·
July 2018ACTIVE
Role of Senescent Cells in Radiation-induced Pulmonary Fibrosis
NATL INST OF HLTH NCI · Principal Investigator
June 2018 – May 2019
The 4th International Cell Senescence Association (ICSA) meeting (ICSA 2018) Resubmission
NATL INST OF HLTH NIA · Principal Investigator
April 2018ACTIVE
Ionizing radiation induced hematological malignancies
NATL INST OF HLTH NCI · Principal Investigator

Education

1986
M.S.
Henan Medical University
1982
M.D.
Yunyang Medical College